Dr. Andre Frenzel YUMAB GMBH, Germany

André Frenzel studied biology at the Johannes Gutenberg University Mainz and the Leibniz University in Hannover, Germany. He received his PhD from the Leibniz Universität in Hannover, Germany, in 2006. In 2006 he joined the Institute of Pharmacology, Toxicology and Clinical Pharmacy before he went back to the University of... read moreHannover in 2007. Since 2009 he has been working at the Institute of Biochemistry, Biotechnology and Bioinformatics at the Technische Universität Braunschweig, Germany.
He has published more than 30 articles (including book chapters and reviews) on the discovery and development of human antibodies and antibody phage display. He is working on the development of human and human-like antibodies for diagnostics and therapy with a focus on cancer and so-called difficult targets.
He co-founded the YUMAB GmbH (www.yumab.com) in 2012 and serves as CSO of the company. YUMAB provides services for the generation and development of antibody molecules.